ArticleJournal of translational medicine2025
Amide proton transfer imaging reveals cerebral metabolic alterations associated with cognitive impairment in type 2 diabetes mellitus.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Letter regarding amide proton transfer imaging reveals cerebral metabolic alterations associated with cognitive impairment in type 2 diabetes mellitus.Journal of translational medicine · 2026Article
- Research Progress on Pathology, Molecular Mechanisms, and Intervention Strategies of Cognitive Dysfunction Associated with Type 2 Diabetes.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAmide proton transfer (APT) imaging indirectly reflects tissue metabolic changes by detecting variations in the concentration of mobile amide protons and tissue pH. Type 2 diabetes mellitus (T2DM) is often accompanied by cognitive dysfunction and diabetic encephalopathy, both of which pose serious threat to human health and quality of life. This study aimed to evaluate the potential of APT imaging as a novel biomarker for detecting cerebral metabolic alterations and to investigate its associations with cognitive impairment in patients with T2DM.
methodsThis study included 32 T2DM patients, comprising 16 with mild cognitive impairment (MCI) and 16 with normal cognition (NC), and 26 healthy controls. Clinical data and cognitive assessments were collected within one week of MRI acquisition. Imaging markers of cerebral small vessel disease (CSVD) were evaluated using AI-assisted tools. APT values were measured in predefined brain regions, including the hippocampus (hipp), temporal white matter (TWM), temporal gray matter (TGM), occipital white matter (OWM), occipital gray matter (OGM), and cerebral peduncles (CPs) using 3D Slicer software. Group differences were analyzed with one-way ANOVA followed by Bonferroni-corrected post hoc tests (or Kruskal-Wallis test with Bonferroni correction for non-parametric data). Partial correlations (Bonferroni-corrected) assessed the links between APT values and cognitive scores, as well as between APT values and CSVD imaging markers.
resultsThe APT values of the left temporal white matter (TWM) and the right temporal gray matter (TGM) were significantly different among the three groups. Among them, the APT values of T2DM-MCI group were significantly lower. In T2DM patients, partial correlation analysis showed that the APT values of the left TWM was positively correlated with MMSE attention and calculation score, MoCA attention score, and the number of lacunar infarcts (LI), and negatively correlated with the severity of white matter hyperintensities (WMH). The APT values of right TGM was positively correlated with MoCA total scores, MoCA visuospatial scores and MoCA delayed recall scores.
conclusionT2DM patients with mild cognitive impairment exhibited significantly lower APT values in the left temporal white matter and right temporal gray matter. These lower APT values were strongly associated with poorer cognitive performance and more severe CSVD. APT imaging may serve as a sensitive, noninvasive biomarker for detecting cerebral metabolic deterioration underlying diabetic cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.